Identification and Characterization of ML321: a Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity
R. B. Free, A. N. Nilson, N. M. Boldizsar, T. Doyle, R. M. Rodriguiz, V. M. Pogorelov, M. Machino, K. H. Lee, J. W. Bertz, J. Xu, H. D. Lim, A. E. Dulcey, R. H. Mach, J. H. Woods, J. R. Lane, , D. R. Sibley
This paper develops ML321, a highly selective D2 dopamine receptor antagonist, showing efficacy in animal models predictive of atypical antipsychotic activity with fewer side effects.
bioRxiv · Nov 14, 2022Pharmacology & Toxicology